Parul N. Barry, MD, FACRO, discussed extending advanced radiation services to satellite sites and offered guidance for early career physicians building new programs.
|Articles|December 13, 2013
Breast Cancer Screening Benefits More Consistent Than Previously Thought
Author(s)Robert A. Smith, PhD
Major studies looking at breast cancer screening with mammography may have more consistent findings than previously thought.
Advertisement
Major studies looking at breast cancer screening with mammography may have more consistent findings than previously thought. Robert A. Smith, PhD, of the American Cancer Society and colleagues re-examined data with common denominators and found interesting results.
Advertisement
Related to this article
Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Flood-Damaged Plant May Prolong US Chemotherapy Shortages to 2028
2
KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS
3
Neoadjuvant BOT + BAL Yields Pathologic Responses in pMMR/dMMR Colon Cancer
4
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
5